Averill Clapp
YOU?
Author Swipe
View article: Clinical use and toxicities of bortezomib in pediatric patients: a systematic review
Clinical use and toxicities of bortezomib in pediatric patients: a systematic review Open
Background Proteasome inhibitors (PIs) are FDA-approved to treat adult malignancies. The PI, Bortezomib (BTZ), has been used off-label in pediatric patients but its safety profile in these patients has yet to be systematically assessed. We…
View article: Infantile Hemangiomas Lose Vascular Endothelial Cadherin During Involution: Potential Role in Cell Death?
Infantile Hemangiomas Lose Vascular Endothelial Cadherin During Involution: Potential Role in Cell Death? Open
Background: Infantile hemangiomas (IHs) are benign endothelial cell (EC) tumors that undergo a predictable natural history, with rapid proliferation, stabilization, and involution. However, mechanisms regulating these transitions are not w…
View article: 77. Vascular Endothelial Growth Factor Receptor 2 and 3 are Mislocalized and Fail to Respond to Flow in Venous Malformations
77. Vascular Endothelial Growth Factor Receptor 2 and 3 are Mislocalized and Fail to Respond to Flow in Venous Malformations Open
Purpose: Venous malformations have been shown to be hyperproliferative lesions. We previously showed that critical junctional proteins, CD31 and VECADHERIN, which are responsible for cell adhesion, flow responses, quiescence, vascular endo…
View article: Utilization of Healthcare Resources by Vascular Anomaly Patients: An Assessment of Healthcare Burden by Lesion Complexity
Utilization of Healthcare Resources by Vascular Anomaly Patients: An Assessment of Healthcare Burden by Lesion Complexity Open
Background: Vascular anomalies (VAs) are heterogeneous lesions. Symptoms vary widely by lesion type and complexity. VA patients often require life-long interdisciplinary care; however, there is a paucity of data on the healthcare utilizati…
View article: Pathophysiology of Slow-Flow Vascular Malformations: Current Understanding and Unanswered Questions
Pathophysiology of Slow-Flow Vascular Malformations: Current Understanding and Unanswered Questions Open
Background: Slow-flow vascular malformations include venous, lymphatic, and lymphaticovenous malformations. Recent studies have linked genetic variants hyperactivating either the PI3K/AKT/mTOR and/or RAS/RAF/MAPK signaling pathways with sl…
View article: 149. Venous Malformation Endothelial Cells Differentially Respond to Laminar Shear Stress
149. Venous Malformation Endothelial Cells Differentially Respond to Laminar Shear Stress Open
PURPOSE: Venous malformations (VeMs) are congenital lesions of the venous system with pathogenic variants most commonly in PIK3CA and TIE2. Previously we and others have demonstrated that unlike normal human microvascular endothelial cells…
View article: 20. Therapeutic Targeting of Protein Homeostasis Defects in Venous Malformations
20. Therapeutic Targeting of Protein Homeostasis Defects in Venous Malformations Open
PURPOSE: Venous malformations (VeMs) are congenital lesions of the vascular system which can cause severe morbidities and mortality, and currently have no cure. Pathogenic variants, most often in PIK3CA, have been identified in VeM endothe…
View article: Regulation of the error-prone DNA polymerase Polκ by oncogenic signaling and its contribution to drug resistance
Regulation of the error-prone DNA polymerase Polκ by oncogenic signaling and its contribution to drug resistance Open
DNA polymerase κ mediates drug resistance in tumor cells through a mechanism that could be independent of mutagenesis.
View article: Regulation of the error-prone DNA polymerase polκ by oncogenic signaling and its contribution to drug resistance
Regulation of the error-prone DNA polymerase polκ by oncogenic signaling and its contribution to drug resistance Open
Mutations in the proofreading domains of the replicative DNA polymerases polδ and polε are associated with elevated mutation rates in cancer, but the roles of other DNA polymerases in tumorigenesis remain poorly understood. One such polyme…